CTOs on the Move

Intarcia Therapeutics, Inc., is a rapidly emerging biopharmaceutical company committed to developing innovative therapies that merge medicine with technology, and have the potential to transform therapeutic categories. We focus our efforts on serious diseases that are prevalent and poorly controlled. Our near-term goal is to deliver a game-changing new level of freedom for a vast number of patients with type 2 diabetes. Our next pipeline target is obesity – another very prevalent and costly health problem confronting the global community. Making real differences in these two areas is our future and our passion. Intarcia`s platform technology is a proprietary subcutaneous delivery system. ...

Intarcia Therapeutics, Inc., is a rapidly emerging biopharmaceutical company committed to developing innovative therapies that merge medicine with technology, and have the potential to transform therapeutic categories. We focus our efforts on serious diseases that are prevalent and poorly controlled. Our near-term goal is to deliver a game-changing new level of freedom for a vast number of patients with type 2 diabetes. Our next pipeline target is obesity – another very prevalent and costly health problem confronting the global community. Making real differences in these two areas is our future and our passion. Intarcia`s platform technology is a proprietary subcutaneous delivery system. The system is comprised of a small, matchstick-sized osmotic pump that is placed sub-dermally (just beneath the skin) to deliver a slow and consistent flow of medication. Each device contains an appropriate volume of drug product to treat a patient for a predetermined extended duration of time. Delivering drugs via this technology avoids unwanted peak drug levels often associated with adverse events and potential suboptimal therapeutic effects. Another key aspect of the technology is the unique formulation that maintains stability of proteins and peptides at human body temperature for extended periods of time, ultimately resulting in the continuous delivery of therapy up to 12 months.

More>>

<<Less